| Chairman |
|
Fu Hang |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman & General Manager: Fu Hang
Executive Director: Zhou Wei
Non-executive Director: Ma Honglan, Wu Shihang, Albert Esteve Cruella, Fei Junjie(formerly known as Fei Jiayuan)
Independent Non-executive Director: Zhou Zhihui, Ho Mei Yi(formerly known as Ho Ling), Zhou Demin.
|
| Principle Business |
|
The Group is principally engaged in the R&D, manufacturing and commercialization of biopharmaceutical products and medical devices, focus on therapeutic areas included orthopedics, metabolic diseases, oncology, and hematology. |
| Major Shareholders |
| Hu Kaijun & ASSO | 29,484,317 | NON-H SHS | 12.01% | 21.63% | 2024/11/28 | | Li Bangliang & ASSO | 28,331,705 | NON-H SHS | 11.55% | 20.79% | 2024/11/28 | | Corporacion Quimico-farmaceutica Esteve, Sociedad Anonima | 24,000,000 | NON-H SHS | 9.78% | 17.61% | 2024/11/28 | | Hangzhou Investment Holdings Co., Ltd. | 17,429,338 | NON-H SHS | 7.10% | 12.79% | 2024/11/28 | | Yang Loon Chun & ASSO | 13,000,000 | H Sh | 5.30% | 11.92% | 2024/11/28 | | Hu Kaijun & ASSO | 12,636,136 | H Sh | 5.15% | 11.58% | 2024/11/28 | | Insigma Technology Co., Ltd. | 12,256,888 | H Sh | 4.99% | 11.23% | 2024/11/28 | | Insigma Technology Co., Ltd. | 12,256,887 | NON-H SHS | 4.99% | 8.99% | 2024/11/28 | | Yang Loon Chun & ASSO | 7,000,000 | NON-H SHS | 2.85% | 5.14% | 2024/11/28 | | Li Bangliang & ASSO | 6,499,630 | H Sh | 2.65% | 5.96% | 2024/11/28 | | Corporacion Quimico-farmaceutica Esteve, Sociedad Anonima | 6,000,000 | H Sh | 2.44% | 5.50% | 2024/11/28 |
|
|
|
|
|